In early 2010, Paul Conforti of Finale, the Boston-area premium dessert restaurant, decided to replace its more traditional mystery shoppers with Survey on the Spot to collect market research data. Survey on the Spot uses a smart phone-based 'app' to collect data from actual customers in real time. Based on early results, Conforti was concerned that the results might be 'too good' and his decision to end mystery shopping might be precipitous. Students can evaluate both the new market research technique and the conclusions drawn from the information. Note: Finale and Survey on the Spot is one of two companion cases. The companion case, Finale - Just Desserts, deals primarily with data analysis and data interpretation and has an SPSS data set available. Finale and Survey on the Spot allows students to deal with the managerial implications of the data.

In early 2010, Paul Conforti of Finale, the Boston-area premium dessert restaurant, decided to replace the more traditional research methods with Survey on the Spot mobile surveys to collect market research data. The company used a smart phone-based 'app' to collect data from actual customers in real time. With early results in, Conforti found that while Finale was getting positive results, he questioned whether his summary provided a complete picture and has asked market researcher Felicity Klass to do a more thorough analysis. Students have access to the mobile survey data and can perform their own analysis, drawing conclusions and making recommendations to the restaurant co-founder, based on stated goals for the survey. Note that Finale-Just Desserts is one of two companion cases. This case, Finale - Just Desserts, deals primarily with data analysis and data interpretation and has an SPSS data set available.

Fisk Alloy Wire was a privately-owned specialty wire mill with facilities in Hawthorne, NJ and Oriskany, NY. The business focused on the development and manufacture of copper alloy wire for electronic components and conductors. Fisk Alloy had developed a copper alloy wire that was cadmium free (cadmium was a known carcinogen affecting both processing and disposal), but also met the characteristics of strength, conductivity, and elongation that defined a high performance wire. The product family, called Percon, was introduced into the market about the time the European Union passed the Restriction of Hazardous Substances ('RoHS') and the related Waste Electrical and Electronic Equipment ('WEEE') directives. The total market potential for Percon was not really known, since it could potentially be used in a broad variety of applications. Fisk Alloy was determined to be the best in its niche of the industry, but not necessarily the biggest. Management recognized that determining how to grow, slowly and opportunistically or more aggressively, would require balancing the market opportunities with the realities of capacity and related production issues.

In early 2009 Andrew Sears, Executive Director of TechMission, a Christian social service nonprofit, faced a challenge known to many not-for-profit organizations, how to develop a sustainable organization, especially in an economic climate where charitable giving had declined. With limited resources and an expanding portfolio of programs, he had to balance three competing factors within TechMission: staying true to its Christian principles, sustaining its credibility in urban communities, and using technology as the driver for promoting social justice. Different initiatives presented different paths for potential growth. As well as determining the correct path, Sears knew that any path would require obtaining additional funding, potentially from secular organizations. The challenge was securing this funding in a tightening market and then allocating it to the initiatives that had the most potential. Additionally, it would be necessary to assure that all initiatives had the right programs, people and funding to move forward.

Syntonix Pharmaceuticals, a Boston biopharmaceutical startup company, was seeking additional financing for growth. The company had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then utilized that technology to develop new therapies to treat chronic diseases. The Transceptor® technology utilized a unique biological pathway to allow efficient delivery of SynFusion™ drug therapies. Several companies licensed the technologies in joint development deals to address several different conditions: Hemophilia B, autoimmune disorders, and infertility, as well as for use in enhanced peptide inhalation. The company had used up Angel money and Rounds A and B of venture capital financing and was looking for an additional $80 - $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to gain a 'C' Round of funding. One member of the proposed syndicate, Biogen Idec, indicated interest in buying Syntonix outright. The founders needed to make a decision about the offer.